NeuroAlign
Medivis, Inc. · Decision date Oct 26, 2026
What did the FDA decide?
Medivis, Inc. received a substantially equivalent (SESE) decision for NeuroAlign, a Class II neurological stereotaxic instrument under 21 CFR 882.4560, product code HAW, in the neurology specialty. The FDA decision date is October 26, 2026; the public 510(k) record lists a June 15, 2026 date received, while the summary cover letter states October 1, 2026. The summary identifies NeuroAlign Software (K231897) as the predicate and describes a software-based cranial image-guided navigation system with an optical see-through head-mounted display.
The changed items are an Atracsys spryTrack 300 external optical tracking camera, used in an external camera tracking mode where the workstation provides the navigation display and the HMD is an optional adjunct, plus added reusable surgical accessories. The summary states clinical testing was not required and that nonclinical results supported the determination. SESE is a 510(k) clearance, not a PMA approval. The summary does not quantify performance results, and the reviewed excerpts do not include the full indications-for-use text or the specific reusable accessories.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Oct 26, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261997
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Medivis, Inc.
- Product code
- HAW
- Decision code
- SESE
- Decision date
- Oct 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Neurological Stereotaxic Instrument.
- Applicant
- Medivis, Inc.
- Product code
- HAW
- FDA device class
- 2
FDA decision timeline
K261997 received
Application receipt date recorded by FDA.
K261997 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code HAW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| inomed Medizintechnik GmbH | 510(k) clearance | Nov 6, 2026 | FDA | |
| Medtronic Navigation | 510(k) clearance | Nov 6, 2026 | FDA | |
| Guangzhou Aimooe Technology Co., Ltd. | 510(k) clearance | Oct 15, 2026 | FDA | |
| Koh Young Technology, Inc. | 510(k) clearance | Sep 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medivis, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- New York, NY
Sources and methodology
- Original FDA record: K261997
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

